Education
About Us
Working with TipRanks
Follow Us
Soleno Therapeutics (SLNO)
:SLNO
SLNO Analyst Ratings
Strong Buy
10 Buy
0 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
SLNO Stock 12 Month Forecast
Average Price Target
$115.00
▲(132.37% Upside)
| Highest Price Target$145.00 | Average Price Target$115.00 | Lowest Price Target$75.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
LifeSci Capital
$110
Buy
122.27%
Upside
Reiterated
12/11/25
Optimistic Outlook for Soleno Therapeutics: Potential Synergy of Vykat in Niche Market SegmentsThis morning, Rhythm Therapeucs (Nasdaq: RYTM) presented limited preliminary data from the ongoing Phase 2a trial evaluang once-daily SQ setmelanode, an MC4R agonist, in 8 of the 18 enrolled Prader– Willi syndrome (PWS) paents with obesity (mean BMI=39.1). As a reminder, this poron of the study is a single-arm, open-label cohort conducted at a single U.S. site. Dr. Miller, a leading PWS KOL and the invesgator enrolling paents, characterized Paents #1–5 as “the worst of the worst,” nong that they were ineligible for SLNO's Vykat due to diabetes and significant baseline edema. Two of the eight paents were on a stable dose of Vykat at baseline, a benefit that is readily apparent in their low baseline HQ-CT scores.
H.C. Wainwright
$110
Buy
122.27%
Upside
Reiterated
11/10/25
Soleno Therapeutics: Strong Q3 Performance and Market Potential Justify Buy RatingValuation and Risks. We have employed a discounted cash flow (DCF)-based approach to assess Soleno's prospects. This utilizes a 10% discount rate, 2% terminal growth rate and 29.84% effective tax rate. We ascribe a 100% probability of U.S. regulatory approval to Soleno's sole marketed product, VYKAT XR (formerly DCCR). Given these parameters, we derive a total firm value of $6.25B, which translates into a 12-month price objective of $110 per share assuming ~56.8M shares outstanding as of mid-2026. Risks include, but are not limited to: (1) slower-than-expected U.S.
Wells Fargo
$123→$106
Buy
114.18%
Upside
Reiterated
11/05/25
Stifel Nicolaus
$115
Buy
132.37%
Upside
Reiterated
11/05/25
Cantor Fitzgerald
$123
Buy
148.54%
Upside
Reiterated
11/04/25
Goldman Sachs
$125
Buy
152.58%
Upside
Initiated
10/07/25
Piper Sandler
$145
Buy
192.99%
Upside
Reiterated
10/03/25
Robert W. Baird
$121
Buy
144.49%
Upside
Reiterated
09/25/25
Oppenheimer
$110
Buy
122.27%
Upside
Reiterated
08/25/25
Guggenheim
$97→$106
Buy
114.18%
Upside
Reiterated
08/06/25
Laidlaw
$75→$105
Buy
112.16%
Upside
Reiterated
03/27/25
Analyst Type
Any
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
LifeSci Capital
$110
Buy
122.27%
Upside
Reiterated
12/11/25
Optimistic Outlook for Soleno Therapeutics: Potential Synergy of Vykat in Niche Market SegmentsThis morning, Rhythm Therapeucs (Nasdaq: RYTM) presented limited preliminary data from the ongoing Phase 2a trial evaluang once-daily SQ setmelanode, an MC4R agonist, in 8 of the 18 enrolled Prader– Willi syndrome (PWS) paents with obesity (mean BMI=39.1). As a reminder, this poron of the study is a single-arm, open-label cohort conducted at a single U.S. site. Dr. Miller, a leading PWS KOL and the invesgator enrolling paents, characterized Paents #1–5 as “the worst of the worst,” nong that they were ineligible for SLNO's Vykat due to diabetes and significant baseline edema. Two of the eight paents were on a stable dose of Vykat at baseline, a benefit that is readily apparent in their low baseline HQ-CT scores.
H.C. Wainwright
$110
Buy
122.27%
Upside
Reiterated
11/10/25
Soleno Therapeutics: Strong Q3 Performance and Market Potential Justify Buy RatingValuation and Risks. We have employed a discounted cash flow (DCF)-based approach to assess Soleno's prospects. This utilizes a 10% discount rate, 2% terminal growth rate and 29.84% effective tax rate. We ascribe a 100% probability of U.S. regulatory approval to Soleno's sole marketed product, VYKAT XR (formerly DCCR). Given these parameters, we derive a total firm value of $6.25B, which translates into a 12-month price objective of $110 per share assuming ~56.8M shares outstanding as of mid-2026. Risks include, but are not limited to: (1) slower-than-expected U.S.
Wells Fargo
$123→$106
Buy
114.18%
Upside
Reiterated
11/05/25
Stifel Nicolaus
$115
Buy
132.37%
Upside
Reiterated
11/05/25
Cantor Fitzgerald
$123
Buy
148.54%
Upside
Reiterated
11/04/25
Goldman Sachs
$125
Buy
152.58%
Upside
Initiated
10/07/25
Piper Sandler
$145
Buy
192.99%
Upside
Reiterated
10/03/25
Robert W. Baird
$121
Buy
144.49%
Upside
Reiterated
09/25/25
Oppenheimer
$110
Buy
122.27%
Upside
Reiterated
08/25/25
Guggenheim
$97→$106
Buy
114.18%
Upside
Reiterated
08/06/25
Laidlaw
$75→$105
Buy
112.16%
Upside
Reiterated
03/27/25
Best Analysts Covering Soleno Therapeutics
1 Month
xxx
Success Rate
6/9 ratings generated profit
Average Return
+7.64%
reiterated a xxx
rating last month
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 66.67% of your transactions generating a profit, with an average return of +7.64% per trade.
3 Months
xxx
Success Rate
7/11 ratings generated profit
Average Return
+78.57%
reiterated a xxx
rating last month
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 63.64% of your transactions generating a profit, with an average return of +78.57% per trade.
1 Year
Success Rate
7/11 ratings generated profit
Average Return
+159.21%
reiterated a buy rating last month
Copying Kristen Kluska's trades and holding each position for 1 Year would result in 63.64% of your transactions generating a profit, with an average return of +159.21% per trade.
2 Years
xxx
Success Rate
7/11 ratings generated profit
Average Return
+155.59%
reiterated a xxx
rating last month
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 63.64% of your transactions generating a profit, with an average return of +155.59% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
SLNO Analyst Recommendation Trends
Rating
Aug 25
Sep 25
Oct 25
Nov 25
Dec 25
Strong Buy
11
22
25
28
16
Buy
11
9
4
0
0
Hold
0
0
0
0
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
22
31
29
28
16
Each month's total comprises the sum of three months' worth of ratings.
SLNO Financial Forecast
SLNO Stock Forecast FAQ
What is SLNO’s average 12-month price target, according to analysts?
Based on analyst ratings, Soleno Therapeutics’s 12-month average price target is 115.00.
What is SLNO’s upside potential, based on the analysts’ average price target?
Soleno Therapeutics has 132.37% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is SLNO a Buy, Sell or Hold?
Soleno Therapeutics has a consensus rating of Strong Buy which is based on 10 buy ratings, 0 hold ratings and 0 sell ratings.
What is Soleno Therapeutics’s price target?
The average price target for Soleno Therapeutics is 115.00. This is based on 10 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $145.00 ,the lowest forecast is $75.00. The average price target represents 132.37% Increase from the current price of $49.49.
The highest analyst price target is $145.00 ,the lowest forecast is $75.00. The average price target represents 132.37% Increase from the current price of $49.49.
What do analysts say about Soleno Therapeutics?
Soleno Therapeutics’s analyst rating consensus is a Strong Buy. This is based on the ratings of 10 Wall Streets Analysts.
How can I buy shares of SLNO?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.